Mucins are a significant extracellular component of neoplastic entities such as
pseudomyxoma peritonei and several gastrointestinal adenocarcinomas. Mucinous tumours …

Simple Summary The drug BromAc® has been used in the treatment of pseudomyxoma
peritonei, a rare peritoneal cancer. Often, patients with pseudomyxoma peritonei require …

Highlights What are the main findings? BromAc is a better mucolytic compared to bromelain
or N-acetylcysteine alone. BromAc reduces the viscosity and increases the flow rate of …

Gemcitabine (GEM) is commonly chosen for treating pancreatic cancer. However, its use is
limited by toxicity. Earlier in vitro studies with GEM in combination with Bromelain (Brom) …

Purpose: The aim of this study was to investigate the effect of bromelain alone and in
combination with Cisplatin on oral squamous cell carcinoma (OSCC) and fibroblast cell …

Single-agent doxorubicin currently forms part of standard care for patients with sarcomas.
However, efficacy is limited by the presence of dose-dependent cardiotoxicity and toxicity to …

Background: Colorectal cancer (CRC) is one of the most prevalent cancers worldwide.
Objective: Considering the side effects of chemotherapy treatments, we reviewed the anti …

Featured Application BromAc a combination of bromelain and NAC, can eradicate mesh
biofilms produced by three strains of Pseudomonas aeruginosa in vitro, with biofilm …

Pancreatic cancer is a deadly disease with a five-year survival rate of less than 5%.
Gemcitabine is the standard of care in the treatment of pancreatic cancer, however …

Respiratory diseases such as cystic fibrosis, COPD, bronchiectasis asthma and COVID-19
are difficult to treat owing to viscous secretions in the airways that evade mucocilliary …